Talphera TLPH
NASDAQ TLPH
$1.23 +0.01 (+0.82%)
As of: Sep 10, 2026 · 3:47 PM EDT

Talphera (TLPH) Income towards Parent Company (2010 - 2026)

Talphera (TLPH) posted Income towards Parent Company of -$3.8 million for Q2 2026, up 0.71% on a QoQ basis from -$3.8 million in Q1 2026, and down 3.93% year-over-year from -$3.9 million in Q2 2025.

Analysis

Talphera (TLPH) Income towards Parent Company (2010 - 2026) Analysis & Trends

Talphera has reported Income towards Parent Company for 17 years, with the latest figure at -$3.8 million in Q2 2026.

  • On a quarterly basis, Income towards Parent Company fell 3.93% year-over-year to -$3.8 million in Q2 2026; TTM through Jun 2026 was -$14.1 million, a 11.81% decrease from a year earlier, with the FY2025 full-year figure at -$13.0 million, up 10.97% from the prior year.
  • Income towards Parent Company was -$3.8 million for Q2 2026 at Talphera, up from -$3.8 million in the prior quarter.
  • The five-year high for Income towards Parent Company was $67.0 million in Q2 2022, with the low at -$13.4 million in Q1 2022.
  • Average Income towards Parent Company over 5 years is $238944.4, with a median of -$3.5 million recorded in 2024.
  • The largest YoY upside for Income towards Parent Company was 780.25% in 2022 against a maximum downside of 1316.97% in 2022.
  • Over 5 years, Income towards Parent Company stood at -$7.7 million in 2022, then soared by 91.47% to -$655000.0 in 2023, then tumbled by 341.68% to -$2.9 million in 2024, then fell by 12.34% to -$3.2 million in 2025, then declined by 15.45% to -$3.8 million in 2026.
  • The last three Income towards Parent Company figures came in at -$3.8 million (Q2 2026), -$3.8 million (Q1 2026), and -$3.2 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 206.58 Bn 192.59 Bn 7.24 Bn
2 Gilead Sciences 180.17 Bn 176.99 Bn 6.22 Bn
3 Vertex Pharmaceuticals 130.59 Bn 122.74 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 81.61 Bn 73.61 Bn 3.93 Bn
5 Argenx Se 60.24 Bn 55.05 Bn 1.37 Bn
6 Moderna 54.29 Bn 49.15 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 32.96 Bn 29.65 Bn 992.69 Mn
8 Biogen 31.94 Bn 30.66 Bn 1.96 Bn
9 Roivant Sciences 29.38 Bn 29.38 Bn 1.16 Mn
10 Talphera 92.90 Mn 92.90 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -3.75 Mn
Mar 31, 2026 -3.78 Mn
Dec 31, 2025 -3.25 Mn
Sep 30, 2025 -3.34 Mn
Jun 30, 2025 -3.61 Mn
Mar 31, 2025 -2.77 Mn
Dec 31, 2024 -2.89 Mn
Sep 30, 2024 -3.35 Mn
Jun 30, 2024 -3.83 Mn
Mar 31, 2024 -4.02 Mn
Dec 31, 2023 -655,000.00
Sep 30, 2023 -1.36 Mn
Jun 30, 2023 -4.37 Mn
Mar 31, 2023 8.22 Mn
Dec 31, 2022 -7.68 Mn
Sep 30, 2022 -8.86 Mn
Jun 30, 2022 67.01 Mn
Mar 31, 2022 -13.41 Mn
Dec 31, 2021 -542,000.00
Sep 30, 2021 -8.38 Mn